About: Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function
Creator	Al, Articlephotochemical, Treatment Plasmasingh,
source	Medline; PMC
abstract	BACKGROUND: The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function. STUDY DESIGN AND METHODS: Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm(2) long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities. RESULTS: The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; Klebsiella pneumoniae, greater than 7.4; Staphylococcus epidermidis and Yersinia enterocolitica, greater than 7.3; Treponema pallidum, greater than 5.9; Borrelia burgdorferi, greater than 10.6; Plasmodium falciparum, 6.9; Trypanosoma cruzi, greater than 5.0; and Babesia microti, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin. CONCLUSION: PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.
has issue date	2006-06-26(xsd:dateTime)
bibo:doi	10.1111/j.1537-2995.2006.00867.x
bibo:pmid	16836564
has license	no-cc
sha1sum (hex)	02975cabb743828cb5ada7170e4c3dfd76a68467
schema:url	https://doi.org/10.1111/j.1537-2995.2006.00867.x
resource representing a document's title	Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function
has PubMed Central identifier	PMC7201872
has PubMed identifier	16836564
schema:publication	Transfusion
resource representing a document's body	covid:02975cabb743828cb5ada7170e4c3dfd76a68467#body_text
is schema:about of	named entity 'FACT' named entity 'prothrombin time' named entity 'protein C' named entity 'West Nile virus' named entity 'FACT' named entity 'ASSAY CONTROL' named entity 'COMPOUND' named entity 'DEVICE' named entity 'ultraviolet' named entity 'photochemical' named entity 'assay' named entity 'von Willebrand' named entity 'ultraviolet' named entity 'protein' named entity 'activated partial thromboplastin time' named entity 'cofactor' named entity 'SARS-CoV' named entity 'duck hepatitis B virus' named entity 'compound' named entity 'enveloped viruses' named entity 'cell membrane' named entity 'viruses' named entity 'detergent' named entity 'HCV' named entity 'syphilis' named entity 'viruses' named entity 'pathogen' named entity 'Plasma' named entity 'CFU' named entity 'antithrombin' named entity 'µmol' named entity 'anticoagulant' named entity 'plasma' named entity 'Y. enterocolitica' named entity 'FFP' named entity 'Coagulation factor' named entity 'µmol' named entity 'SARS' named entity 'plasma' named entity 'plasma' named entity 'detergent' named entity 'polio virus' named entity 'viral hepatitis' named entity 'absorbance' named entity 'plasma' named entity 'HBV' named entity 'Trypanosoma cruzi' named entity 'T. pallidum' named entity 'chromogenic' named entity 'hepatitis A virus' named entity 'United States' named entity 'capsid' named entity 'FFP' named entity 'plasma' named entity 'Soluble' named entity 'P. falciparum' named entity 'fresh-frozen plasma' named entity 'reagent' named entity 'log reduction' named entity 'VWF' named entity 'clotting time' named entity 'HBV' named entity 'Chagas' named entity 'FDA' named entity 'liver disease' named entity 'blood components' named entity 'coagulopathy' named entity 'viruses' named entity 'hemostasis' named entity 'methylene blue' named entity 'coagulation' named entity 'blood products' named entity 'Babesia microti' named entity 'plasma' named entity 'flavivirus' named entity 'pathogen inactivation' named entity 'plasmapheresis' named entity 'plasma' named entity 'window period'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software